Erik Aragon, MD
Neurology · Winter Park, FLNPI 1770585556
Payments from drug & device makers
Across 354 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$790
- Biogen$661
- EMD Serono, Inc.$572
- UCB, Inc.$374
- AbbVie$363
- Teva Pharmaceuticals USA, Inc.$362
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$240%
- Food & beverage$5,162100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 90 | $790 |
| Biogen | 42 | $661 |
| EMD Serono, Inc. | 37 | $572 |
| UCB, Inc. | 19 | $374 |
| AbbVie(2 entities) | 22 | $363 |
| Teva Pharmaceuticals USA, Inc. | 32 | $362 |
| Lilly USA, LLC | 20 | $340 |
| Eisai Inc. | 13 | $246 |
| Genentech USA, Inc. | 13 | $190 |
| Sanofi | 7 | $161 |
| Acadia Pharmaceuticals Inc | 9 | $151 |
| Argenx US, Inc. | 6 | $127 |
| CSL Behring | 5 | $98 |
| Mallinckrodt Hospital Products Inc. | 4 | $84 |
| AstraZeneca | 4 | $72 |
| Livanova USA, Inc. | 4 | $70 |
| Neurocrine Biosciences, Inc. | 3 | $67 |
| Lundbeck LLC | 3 | $65 |
| GE HealthCare | 3 | $61 |
| Acorda Therapeutics, Inc | 3 | $57 |
| Amgen | 2 | $45 |
| Bausch Health US, LLC | 2 | $41 |
| Pfizer | 1 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Bristol Myers Squibb | 2 | $28 |
| Grifols USA, LLC | 2 | $25 |
| MDD US Operations, LLC | 1 | $22 |
| Akcea Therapeutics, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$5,186 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 38 | $2,979 |
| Carbamazepine | 13 | $680 |
| Amitriptyline Hcl | 16 | $398 |
| Primidone | 11 | $328 |
| Duloxetine Hcl | 14 | $155 |
| Pregabalin | 11 | $143 |
| Donepezil Hcl | 12 | $130 |
| Topiramate | 11 | $125 |
Paid to pharmacies, not to this prescriber.
Other neurology in Winter Park
- Rekha GandhiWinter Park$13.4M
- Sheila Baez-TorresWinter Park$12.5M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.